Please assess the completion status of the following clinical trial:

Trial Title: Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets DSM-IV criteria for Schizophrenia~* 18-60 years of age or older~* Able to give informed consent~* Treated with olanzapine, quetiapine, risperidone or ziprasidone for greater than or equal to 3 months prior to enrollment~Exclusion Criteria:~* pregnant or breastfeeding women will be excluded~* Meets DSM-IV criteria for substance abuse or dependence within past 6 months~* involuntary legal status (as per Missouri law)~* any serious medical disorder that may confound assessment of symptoms~* subjects taking prescription medications except psychotropic meds~* meets DSM-IV criteria for Mental Retardation (mild or worse)~* Subjects taking tricyclic antidepressants or mood stabilizers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Stayers (Type: OTHER): Subjects are randomized to stay on their current antipsychotic.
- Switchers (Type: OTHER): Subjects are randomized to switch to aripiprazole from their current antipsychotic.

Based on this trial design, predict the completion outcome and termination type (if applicable).